Aaron S. Mansfield

19.9k total citations · 2 hit papers
254 papers, 6.2k citations indexed

About

Aaron S. Mansfield is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Aaron S. Mansfield has authored 254 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 155 papers in Oncology, 114 papers in Pulmonary and Respiratory Medicine and 37 papers in Molecular Biology. Recurrent topics in Aaron S. Mansfield's work include Lung Cancer Treatments and Mutations (68 papers), Cancer Immunotherapy and Biomarkers (57 papers) and Lung Cancer Research Studies (52 papers). Aaron S. Mansfield is often cited by papers focused on Lung Cancer Treatments and Mutations (68 papers), Cancer Immunotherapy and Biomarkers (57 papers) and Lung Cancer Research Studies (52 papers). Aaron S. Mansfield collaborates with scholars based in United States, United Kingdom and France. Aaron S. Mansfield's co-authors include Haidong Dong, Susan M. Harrington, Alex A. Adjei, Roxana Dronca, Tobias Peikert, Svetomir N. Markovic, Konstantinos Leventakos, Justin C. Moser, Eugene D. Kwon and Xin Liu and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Aaron S. Mansfield

231 papers receiving 6.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

2021 484 citations Stephen V. Liu, Martin Reck et al. Journal of Clinical Oncology profile →
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

2022 158 citations Arnaud Scherpereel, Paul Baas et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aaron S. Mansfield United States	40	3.8k	2.4k	1.2k	1.0k	1.0k	254	6.2k
Gregory A. Masters United States	36	4.1k 1.1×	4.0k 1.7×	1.3k 1.1×	849 0.8×	625 0.6×	127	6.9k
Jarushka Naidoo United States	39	5.7k 1.5×	2.6k 1.1×	981 0.8×	1.4k 1.4×	853 0.8×	176	7.2k
Lizza Hendriks Netherlands	36	3.2k 0.9×	3.0k 1.3×	820 0.7×	420 0.4×	538 0.5×	221	5.1k
Lars Bastholt Denmark	42	4.2k 1.1×	1.7k 0.7×	1.8k 1.5×	1.1k 1.1×	984 1.0×	183	8.3k
Shouhao Zhou United States	31	4.5k 1.2×	1.3k 0.6×	1.1k 0.9×	918 0.9×	2.8k 2.8×	162	7.9k
Charles Butts Canada	32	3.5k 0.9×	2.6k 1.1×	1.1k 0.9×	778 0.8×	306 0.3×	96	5.3k
Francisco Vera-Badillo Canada	27	3.4k 0.9×	1.6k 0.7×	754 0.6×	656 0.6×	397 0.4×	76	5.5k
Siow Ming Lee United Kingdom	38	2.4k 0.6×	2.0k 0.8×	1.6k 1.3×	417 0.4×	695 0.7×	171	4.9k
Emilio Bria Italy	46	4.0k 1.0×	2.8k 1.2×	1.8k 1.5×	618 0.6×	495 0.5×	392	7.1k
Jean‐Philippe Spano France	38	3.0k 0.8×	1.2k 0.5×	1.1k 0.9×	501 0.5×	477 0.5×	190	5.1k

Countries citing papers authored by Aaron S. Mansfield

Since Specialization

Citations

This map shows the geographic impact of Aaron S. Mansfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron S. Mansfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron S. Mansfield more than expected).

Fields of papers citing papers by Aaron S. Mansfield

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron S. Mansfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron S. Mansfield. The network helps show where Aaron S. Mansfield may publish in the future.

Co-authorship network of co-authors of Aaron S. Mansfield

This figure shows the co-authorship network connecting the top 25 collaborators of Aaron S. Mansfield. A scholar is included among the top collaborators of Aaron S. Mansfield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aaron S. Mansfield. Aaron S. Mansfield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hazim, Antonious, An Xiao, Aditi P. Singh, et al.. (2024). EP.07C.16 Real-World Outcomes of Patients with Resectable Early-Stage Non-Small Cell Lung Cancer Treated with Neoadjuvant Chemoimmunotherapy. Journal of Thoracic Oncology. 19(10). S546–S547.

Desai, Aakash, Daheui Choi, Þorvarður R. Hálfdánarson, et al.. (2024). Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Cancers. 16(10). 1861–1861. 1 indexed citations

Sabari, Joshua K., Nicolas Girard, Aaron S. Mansfield, et al.. (2024). Plain language summary of PAPILLON: amivantamab plus chemotherapy in untreated EGFR -mutated non-small-cell lung cancer. Future Oncology. 20(32). 2409–2421. 1 indexed citations

Parikh, Kaushal, Anastasios Dimou, Konstantinos Leventakos, et al.. (2024). Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database. Journal of Thoracic Oncology. 19(11). 1539–1549. 11 indexed citations

Barham, Whitney, Xin Liu, Susan M. Harrington, et al.. (2023). A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration–Approved PD-1 and PD-L1 Inhibitors. ImmunoHorizons. 7(1). 125–139. 6 indexed citations

Girard, N., K. Park, Kun Tang, et al.. (2023). LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study. Annals of Oncology. 34. S1304–S1304. 5 indexed citations

Naing, Aung, John D. Powderly, John Nemunaitis, et al.. (2022). Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. Journal for ImmunoTherapy of Cancer. 10(3). e004223–e004223. 12 indexed citations

Dolezal, James M., Andrew Srisuwananukorn, Dmitry Karpeyev, et al.. (2022). Uncertainty-informed deep learning models enable high-confidence predictions for digital histopathology. Nature Communications. 13(1). 6572–6572. 75 indexed citations

Kanakkanthara, Arun, Xiaonan Hou, Valentina Zanfagnin, et al.. (2021). Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma. Cancer Research. 82(2). 307–319. 14 indexed citations

10.

Liu, Stephen V., Martin Reck, Aaron S. Mansfield, et al.. (2021). Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). Journal of Clinical Oncology. 39(6). 619–630. 484 indexed citations breakdown →

11.

Breen, William G., Elizabeth B. Jeans, Yolanda I. Garces, et al.. (2021). Ablative radiotherapy for ultracentral lung cancers: Dosimetric, geometric, and volumetric predictors of outcomes and toxicity. Radiotherapy and Oncology. 158. 246–252. 13 indexed citations

12.

Busacca, Sara, Laura O’Regan, Annabel Sharkey, et al.. (2020). BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma. Molecular Cancer Therapeutics. 20(2). 379–388. 13 indexed citations

13.

Wong, William B., Ning Wu, Ravindra K. Gupta, & Aaron S. Mansfield. (2020). Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non–small-cell Lung Cancer in US Community Practices. Clinical Lung Cancer. 22(3). e470–e480. 11 indexed citations

14.

Ruddy, Kathryn J., Aaron S. Mansfield, Nansu Zong, et al.. (2020). Detecting and Filtering Immune-Related Adverse Events Signal Based on Text Mining and Observational Health Data Sciences and Informatics Common Data Model: Framework Development Study. JMIR Medical Informatics. 8(6). e17353–e17353. 8 indexed citations

15.

Shah, Kabeer, Jadee Neff, Lori A. Erickson, et al.. (2020). Correlation of novel ALK^ATI with ALK immunohistochemistry and clinical outcomes in metastatic melanoma. Histopathology. 77(4). 601–610. 5 indexed citations

16.

Mansfield, Aaron S., Hongzheng Ren, Shari L. Sutor, et al.. (2018). Contraction of T cell richness in lung cancer brain metastases. Scientific Reports. 8(1). 2171–2171. 65 indexed citations

17.

Enninga, Elizabeth Ann L., Justin C. Moser, Amy L. Weaver, et al.. (2017). Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011. Cancer Medicine. 6(10). 2203–2212. 101 indexed citations

18.

Mansfield, Aaron S., et al.. (2016). The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects. Clinical Cancer Research. 22(22). 5472–5479. 21 indexed citations

19.

Park, Sean S., Haidong Dong, Xin Liu, et al.. (2015). PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer Immunology Research. 3(6). 610–619. 303 indexed citations

20.

Mansfield, Aaron S., Stephen J. Murphy, Tobias Peikert, et al.. (2015). Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer. Clinical Cancer Research. 22(9). 2177–2182. 105 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact